Does Rallies show Form 4 insider transactions for JUNS?

Yes. Rallies tracks JUNS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is JUNS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for JUNS. It does not provide personalized investment advice.

JUNS (Jupiter Neurosciences, Inc. Common Stock) Stock Analysis - Insider Trades

Jupiter Neurosciences, Inc. Common Stock (JUNS) is a publicly traded Healthcare sector company. As of May 20, 2026, JUNS trades at $0.35 with a market cap of $12.06M and a P/E ratio of -1.38. JUNS moved +7.81% today. Year to date, JUNS is -68.32%; over the trailing twelve months it is -43.16%. Its 52-week range spans $0.31 to $19.51. Rallies surfaces JUNS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading JUNS stock inside the company?

Recent JUNS insider activity includes Silva Alison D. bought 250, Silva Alison D. bought 250, Silva Alison D. bought 250, ROSEN CHRISTER bought 500, and ROSEN CHRISTER bought 3.10K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

JUNS Key Metrics

Key financial metrics for JUNS
Metric	Value
Price	$0.35
Market Cap	$12.06M
P/E Ratio	-1.38
EPS	$-0.25
Dividend Yield	0.00%
52-Week High	$19.51
52-Week Low	$0.31
Volume	194.68M
Avg Volume	0
Revenue (TTM)	$21.80K
Net Income	$-8.64M
Gross Margin	0.00%

Recent JUNS Insider Trades

Silva Alison D. bought 250 (~$256.575) on Jul 1, 2025.
Silva Alison D. bought 250 (~$257.175) on Jul 1, 2025.
Silva Alison D. bought 250 (~$258.5) on Jul 1, 2025.
ROSEN CHRISTER bought 500 (~$505) on Jul 1, 2025.
ROSEN CHRISTER bought 3.10K (~$3.16K) on Jul 1, 2025.

Latest JUNS News

Jupiter Neurosciences Secures $100M Term Sheet for ALA-002 MDMA U.S. Rights — May 20, 2026
Jupiter Neurosciences to Showcase JOTROL Platform at 9:00 AM ET Wall Street Summit May 5 — May 4, 2026
Jupiter Neurosciences Highlights FDA-Cleared Phase IIa Parkinson’s Trial and Nugevia™ 25% Repeat Buys — Mar 2, 2026
Jupiter Neurosciences Tapped to Showcase Phase IIa and Nugevia™ Updates at Mar-a-Lago Investor Dinner — Feb 25, 2026
Jupiter Neurosciences Defers $6M Convertible Note Repayments to April 2026 — Feb 23, 2026

JUNS Analyst Consensus

JUNS analyst coverage data. Average price target: $0.00.

Common questions about JUNS

Who is trading JUNS stock inside the company?: Recent JUNS insider activity includes Silva Alison D. bought 250, Silva Alison D. bought 250, Silva Alison D. bought 250, ROSEN CHRISTER bought 500, and ROSEN CHRISTER bought 3.10K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for JUNS?: Yes. Rallies tracks JUNS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is JUNS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for JUNS. It does not provide personalized investment advice.